Knowstox

Fundamentals snapshot

Rockwell Medical, Inc.

RMTI · NCM · Healthcare · Drug Manufacturers - Specialty & Generic

Current price

$7.08

52-week range

$4.89 - $12.90

Market cap

$28.54M

One-glance verdict

Undervalued

$16.75 our estimate vs market $7.08

Wall Street consensus: $20.00 (19.4% higher than our fair-value estimate)

Balance sheet

Healthy

-4.17x Concerning

Net cash $10.86M. Interest coverage shows how many times profit covers the interest bill.

What this company does

Rockwell Medical, Inc.

Rockwell Medical makes and sells products that help people with kidney failure through dialysis, which is a process to remove waste from their blood when their kidneys can't. Their main products are different kinds of concentrates that go into the dialysis machines, and the money they make primarily comes from selling these essential supplies to dialysis clinics. This matters because it shows how the company earns its living by providing critical items for a vital medical treatment.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q3 $4.08M FY2024 Q4 $470.00K FY2025 Q1 $-3.55M FY2025 Q2 $1.68M FY2025 Q3 $-1.54M FY2025 Q4 $2.21M FY2026 Q1 $-592.00K FY2026 Q2 $1.46M
Revenue —
Net income $-1.17M
Diluted EPS -0.70
Operating cash flow $2.08M
Free cash flow $1.46M
Revenue —
Net income $-1.60M
Diluted EPS -0.04
Operating cash flow $-167.00K
Free cash flow $-592.00K
Revenue —
Net income $-554.00K
Diluted EPS -0.01
Operating cash flow $2.29M
Free cash flow $2.21M
Revenue —
Net income $-1.75M
Diluted EPS -0.05
Operating cash flow $-1.31M
Free cash flow $-1.54M
Revenue —
Net income $-1.49M
Diluted EPS -0.05
Operating cash flow $1.84M
Free cash flow $1.68M
Revenue —
Net income $-1.51M
Diluted EPS -0.04
Operating cash flow $-3.49M
Free cash flow $-3.55M
Revenue —
Net income $-756.00K
Diluted EPS -0.02
Operating cash flow $865.00K
Free cash flow $470.00K
Revenue —
Net income $1.66M
Diluted EPS 0.04
Operating cash flow $4.28M
Free cash flow $4.08M

Is it cheap or expensive?

Fair value $16.75 vs current price $7.08

Wall Street consensus is the average analyst price target: $20.00 (19.4% higher than our fair-value estimate).

Our most-likely fair value is $16.75 a share — about 136.6% above today's price of $7.08, so the stock currently looks cheap (undervalued).

undervalued

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Base

Growth 10.0% · Discount 11.4% · Terminal 3.0%

$16.75

Bear

Growth 3.0% · Discount 11.4% · Terminal 3.0%

$12.36

Bull

Growth 25.0% · Discount 11.4% · Terminal 3.0%

$33.31

Is it drowning in debt?

Healthy

Net cash $10.9M - more cash than debt. Interest coverage -4.2x.

Net debt $-10.86M
Interest coverage -4.17x

Rockwell Medical, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.

Healthy
Worse cushion Baseline Better cushion
RMTI BASELINE Rockwell Medical, Inc.

Total debt $13.93M Interest coverage -4.17x This is the baseline the peer rows are being compared against.

Total debt $872.00K Interest coverage 1,146.00x This peer still has a real interest-payment cushion, while RMTI does not.

Total debt $7.46M Interest coverage -98.59x Neither company has much profit cushion over interest right now.

Total debt $973.89K Interest coverage -162.33x Neither company has much profit cushion over interest right now.

Total debt $2.66M Interest coverage -310.21x Neither company has much profit cushion over interest right now.

What you should know

The case for and against RMTI

2 Rewards 2 Risks

Rewards

  • Revenue grew 7.5% last year.
  • Free cash flow was positive in 1/10 years.

Risks

  • Return on equity was -15.5% last year — the company lost money on shareholders' equity.
  • Insider ownership is only 14.8% (peer median: 17.0%).

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
101.14x
P/B
0.80x
P/S
0.41x
EV/EBITDA
-7.65x
PEG ratio
4.43x

Profitability

How much profit each dollar creates

Gross margin
17.7%
Operating margin
-6.5%
Net margin
-7.3%
ROE
-15.5%
ROA
-5.2%

Health

Liquidity and balance-sheet strength

Debt / equity
0.40x
Current ratio
3.25x
Quick ratio
2.96x
Total debt
$13.93M
Total cash
$24.80M

Growth

How the business has been compounding

Revenue TTM
$57.30M
Revenue 5Y CAGR
2.3%
EPS TTM
-1.34
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$2.90M
Free CF TTM
$-1.20M
FCF margin
-2.1%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—